- Home
- CHRS vs KVAC Comparison
CHRS vs KVAC Comparison
Compare CHRS & KVAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHRS
- KVAC
- Stock Information
- Founded
- CHRS 2010
- KVAC 2021
- Country
- CHRS United States
- KVAC United States
- Employees
- CHRS N/A
- KVAC N/A
- Industry
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- KVAC
- Sector
- CHRS Health Care
- KVAC
- Exchange
- CHRS Nasdaq
- KVAC Nasdaq
- Market Cap
- CHRS 185.5M
- KVAC 212.1M
- IPO Year
- CHRS 2014
- KVAC 2023
- Fundamental
- Price
- CHRS $1.52
- KVAC $10.96
- Analyst Decision
- CHRS Strong Buy
- KVAC
- Analyst Count
- CHRS 4
- KVAC 0
- Target Price
- CHRS $5.38
- KVAC N/A
- AVG Volume (30 Days)
- CHRS 10.1M
- KVAC 2.7K
- Earning Date
- CHRS 11-06-2024
- KVAC 01-01-0001
- Dividend Yield
- CHRS N/A
- KVAC N/A
- EPS Growth
- CHRS N/A
- KVAC N/A
- EPS
- CHRS N/A
- KVAC 0.43
- Revenue
- CHRS $304,340,000.00
- KVAC N/A
- Revenue This Year
- CHRS $1.64
- KVAC N/A
- Revenue Next Year
- CHRS $16.98
- KVAC N/A
- P/E Ratio
- CHRS N/A
- KVAC $25.38
- Revenue Growth
- CHRS 44.19
- KVAC N/A
- 52 Week Low
- CHRS $0.66
- KVAC $10.33
- 52 Week High
- CHRS $3.70
- KVAC $10.97
- Technical
- Relative Strength Index (RSI)
- CHRS 52.47
- KVAC 85.76
- Support Level
- CHRS $1.45
- KVAC $10.92
- Resistance Level
- CHRS $1.85
- KVAC $10.91
- Average True Range (ATR)
- CHRS 0.23
- KVAC 0.00
- MACD
- CHRS -0.03
- KVAC 0.00
- Stochastic Oscillator
- CHRS 3.88
- KVAC 100.00
About CHRS Coherus BioSciences Inc.
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. The company is focused on the research, development, and commercialization of its portfolio of FDA-approved oncology products, including LOQTORZI. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company generates revenue from the United States.
About KVAC Keen Vision Acquisition Corporation
Keen Vision Acquisition Corp is a blank check company.